Intervacc
+Subscribe to companyCoverage
- Addtech
- Alcadon
- Arise
- Avensia
- Bergs Timber
- BioGaia
- Biovica
- Boule Diagnostics
- Bredband2
- Brighter
- Briox
- Capacent
- Catella
- Catena
- Catena Media
- Cavotec
- Concordia Maritime
- Crown Energy
- CTT Systems
- Dedicare
- DistIT
- Diös
- Doro
- Elanders
- Elos Medtech
- Empir Group
- ENLABS
- Enzymatica
- Eolus Vind
- Eurocon
- eWork
- FastPartner
- Ferronordic
- Formpipe
- Fortnox
- Future Gaming Group
- G5 Entertainment
- GARO
- Generic
- Hifab
- Hoylu
- Intervacc
- INVISIO Communications
- ITAB Shop Concept
- JLT Mobile Computers
- Lagercrantz
- Lammhults
- Leading Edge Materials
- Magnolia Bostad
- MedicaNatumin
- Midsona
- Moment Group
- Motion Display
- NAXS
- Nilörngruppen
- Nolato
- Nordic Waterproofing
- Opus Group
- Poolia
- Pricer
- Proact
- Probi
- QuickCool
- Rottneros
- Seafire
- SinterCast
- SJR
- Stendörren
- Studsvik
- Swedencare
- Swedol
- Tethys Oil
- THQ Nordic
- VBG Group
- Vitec
- Vitrolife
- Zutec
Menu
- Addtech
- Alcadon
- Arise
- Avensia
- Bergs Timber
- BioGaia
- Biovica
- Boule Diagnostics
- Bredband2
- Brighter
- Briox
- Capacent
- Catella
- Catena
- Catena Media
- Cavotec
- Concordia Maritime
- Crown Energy
- CTT Systems
- Dedicare
- DistIT
- Diös
- Doro
- Elanders
- Elos Medtech
- Empir Group
- ENLABS
- Enzymatica
- Eolus Vind
- Eurocon
- eWork
- FastPartner
- Ferronordic
- Formpipe
- Fortnox
- Future Gaming Group
- G5 Entertainment
- GARO
- Generic
- Hifab
- Hoylu
- Intervacc
- INVISIO Communications
- ITAB Shop Concept
- JLT Mobile Computers
- Lagercrantz
- Lammhults
- Leading Edge Materials
- Magnolia Bostad
- MedicaNatumin
- Midsona
- Moment Group
- Motion Display
- NAXS
- Nilörngruppen
- Nolato
- Nordic Waterproofing
- Opus Group
- Poolia
- Pricer
- Proact
- Probi
- QuickCool
- Rottneros
- Seafire
- SinterCast
- SJR
- Stendörren
- Studsvik
- Swedencare
- Swedol
- Tethys Oil
- THQ Nordic
- VBG Group
- Vitec
- Vitrolife
- Zutec
Press the button and be introduced to a new random company!
Introduce me >UPCOMING EVENTS
We arrange several open investor events with our covered companies each year. Please subscribe to get information about our upcoming Introduce events.
Vaccines and pharmaceuticals for animal health
Intervacc
Intervacc is a Swedish company which develops vaccines against infectious bacteria, focused on the animal health care market. According to Intervacc’s management, the technology platform can be used to develop vaccines for any bacterial species, in principle. The company’s subsidiary, Nordvacc, distributes veterinary vaccines across the Nordic and Baltic regions, as well as in the Netherlands. Intervacc has been listed on Nasdaq First North since 2017.
The company has a strong scientific foundation underlying its revolutionary bacterial vaccine development platform. The opportunity to entry into the veterinary market, with Intervacc’s lead product Strangvac, represents a comparatively low-risk commercialisation strategy.
Regulators could demand additional data before approving the company’s lead product. Potential distribution partners may not sell Intervacc’s products as zealously as the company itself would. Competitive, regulatory, and intellectual property rights risks are significant, as with all biotech companies.
Financials
INTERVACC
| SEKm | 2013 | 2013 | 2014 | 2014 | 2015 | 2015 | 2016 | 2016 | 2017 | 2017 | 2018 | 2018 | 2019e | 2019 | 2020e | 2020 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 38 | 0 | 0 | 78 | 78 | 63 | 63 | 56 | 56 | 48 | 48 | 38 | 38 | 40 | 40 | 42 | 42 | ||
| Sales growth (%) | -20 | N/A | N/A | N/A | N/A | -19,5 | -19,5 | -11,5 | -11,5 | -13,6 | -13,6 | -20 | -20 | 5 | 5 | 5 | 5 | ||
| EBITDA | -8 | 0 | 0 | 17 | 17 | 8 | 8 | -1 | -1 | -7 | -7 | -8 | -8 | -25 | -25 | N/A | N/A | ||
| EBITDA margin (%) | -15 | N/A | N/A | N/A | N/A | 21,3 | 21,3 | 13,5 | 13,5 | -2 | -2 | -15 | -15 | -21,3 | -21,3 | -62,6 | -62,6 | ||
| EBIT adj | -14 | 0 | 0 | 0 | 0 | 10 | 10 | 2 | 2 | -7 | -7 | -14 | -14 | -23 | -23 | -32 | -32 | ||
| EBIT adj margin (%) | -28,5 | N/A | N/A | N/A | N/A | 13 | 13 | 3,3 | 3,3 | -13,3 | -13,3 | -28,5 | -28,5 | -59,8 | -59,8 | -78,3 | -78,3 | ||
| Pretax profit | -23 | 0 | 0 | 10 | 10 | 1 | 1 | -8 | -8 | -14 | -14 | -23 | -23 | -32 | -32 | 2 | 2 | ||
| EPS rep | -0,49 | 0 | 0 | 0,24 | 0,24 | 0 | 0 | -0,61 | -0,61 | -1,15 | -1,15 | -0,49 | -0,49 | -0,84 | -0,84 | 0,04 | 0,04 | ||
| EPS growth (%) | 57,5 | N/A | N/A | 0 | 0 | -98,5 | -98,5 | -17740,3 | -17740,3 | -87,6 | -87,6 | 57,5 | 57,5 | -73,5 | -73,5 | 105,1 | 105,1 | ||
| EPS adj | -0,49 | 0 | 0 | 0,24 | 0,24 | 0 | 0 | -0,61 | -0,61 | -1,15 | -1,15 | -0,49 | -0,49 | -0,84 | -0,84 | 0,04 | 0,04 | ||
| DPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| EV/EBITDA (x) | -35,1 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -8,7 | -8,7 | -35,1 | -35,1 | -10,7 | -10,7 | 31 | 31 | ||
| EV/EBIT adj (x) | -12,5 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -4,6 | -4,6 | -12,5 | -12,5 | -8,5 | -8,5 | 137,3 | 137,3 | ||
| P/E (x) | -16,8 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -6,4 | -6,4 | -16,8 | -16,8 | -9,7 | -9,7 | 189,4 | 189,4 | ||
| P/E adj (x) | -16,8 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -6,4 | -6,4 | -16,8 | -16,8 | -9,7 | -9,7 | 189,4 | 189,4 | ||
| EV/sales (x) | 7,5 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1,3 | 1,3 | 7,5 | 7,5 | 6,7 | 6,7 | 6 | 6 | ||
| FCF yield (%) | -6,2 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -38,8 | -38,8 | -6,2 | -6,2 | -8,1 | -8,1 | -5,8 | -5,8 | ||
| Dividend yield (%) | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Net IB debt/EBITDA | 2,5 | N/A | N/A | -0,2 | -0,2 | 0,2 | 0,2 | -6,5 | -6,5 | 2,7 | 2,7 | 2,5 | 2,5 | 1,5 | 1,5 | -6,4 | -6,4 |
| SEKm | 2013 | 2013 | 2014 | 2014 | 2015 | 2015 | 2016 | 2016 | 2017 | 2017 | 2018 | 2018 | 2019e | 2019 | 2020e | 2020 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 38 | 0 | 0 | 78 | 78 | 63 | 63 | 56 | 56 | 48 | 48 | 38 | 38 | 40 | 40 | 42 | 42 | ||
| COGS | -32 | 0 | 0 | -44 | -44 | -36 | -36 | -41 | -41 | -35 | -35 | -32 | -32 | -53 | -53 | -21 | -21 | ||
| Gross profit | 6 | 0 | 0 | 34 | 34 | 27 | 27 | 15 | 15 | 13 | 13 | 6 | 6 | -12 | -12 | 21 | 21 | ||
| Other operating items | -14 | 0 | 0 | -18 | -18 | -18 | -18 | -16 | -16 | -20 | -20 | -14 | -14 | -13 | -13 | -13 | -13 | ||
| EBITDA | -8 | 0 | 0 | 17 | 17 | 8 | 8 | -1 | -1 | -7 | -7 | -8 | -8 | -25 | -25 | 8 | 8 | ||
| Depreciation on tangibles | -9 | 0 | 0 | -1 | -1 | -1 | -1 | 0 | 0 | -1 | -1 | -9 | -9 | 0 | 0 | 0 | 0 | ||
| Depreciation on intangibles | -6 | 0 | 0 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | ||
| EBITA | -23 | 0 | 0 | 10 | 10 | 2 | 2 | -7 | -7 | -14 | -14 | -23 | -23 | -32 | -32 | 2 | 2 | ||
| Goodwill impairment charges | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other impairment and amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| EBIT | -23 | 0 | 0 | 10 | 10 | 2 | 2 | -7 | -7 | -14 | -14 | -23 | -23 | -32 | -32 | 2 | 2 | ||
| Other financial items | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Net financial items | 0 | 0 | 0 | -1 | -1 | -1 | -1 | -1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Associated income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other EO items | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Pretax profit | -23 | 0 | 0 | 10 | 10 | 1 | 1 | -8 | -8 | -14 | -14 | -23 | -23 | -32 | -32 | 2 | 2 | ||
| Tax | 5 | 0 | 0 | 0 | 0 | -1 | -1 | 1 | 1 | 1 | 1 | 5 | 5 | 0 | 0 | 0 | 0 | ||
| Net profit | -18 | 0 | 0 | 9 | 9 | 0 | 0 | -7 | -7 | -13 | -13 | -18 | -18 | -32 | -32 | 2 | 2 | ||
| Minority interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Net profit discontinued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Net profit to shareholders | -18 | 0 | 0 | 9 | 9 | 0 | 0 | -7 | -7 | -13 | -13 | -18 | -18 | -32 | -32 | 2 | 2 | ||
| EPS | -0,49 | 0 | 0 | 0,24 | 0,24 | 0 | 0 | -0,61 | -0,61 | -1,15 | -1,15 | -0,49 | -0,49 | -0,84 | -0,84 | 0,04 | 0,04 | ||
| EPS Adj | -0,49 | 0 | 0 | 0,24 | 0,24 | 0 | 0 | -0,61 | -0,61 | -1,15 | -1,15 | -0,49 | -0,49 | -0,84 | -0,84 | 0,04 | 0,04 | ||
| Total extraordinary items after tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Tax rate (%) | -20,7 | N/A | N/A | -2,9 | -2,9 | -89,4 | -89,4 | -14,3 | -14,3 | -9,6 | -9,6 | -20,7 | -20,7 | 0 | 0 | 0 | 0 | ||
| Gross margin (%) | 15,5 | N/A | N/A | 43,9 | 43,9 | 42,8 | 42,8 | 27,1 | 27,1 | 27 | 27 | 15,5 | 15,5 | -30,4 | -30,4 | 50 | 50 | ||
| EBITDA margin (%) | -21,3 | N/A | N/A | 21,3 | 21,3 | 13,5 | 13,5 | -2 | -2 | -15 | -15 | -21,3 | -21,3 | -62,6 | -62,6 | 19,4 | 19,4 | ||
| EBITA margin (%) | -59,8 | N/A | N/A | 13 | 13 | 3,3 | 3,3 | -13,3 | -13,3 | -28,5 | -28,5 | -59,8 | -59,8 | -78,3 | -78,3 | 4,4 | 4,4 | ||
| EBIT margin (%) | -59,8 | N/A | N/A | 13 | 13 | 3,3 | 3,3 | -13,3 | -13,3 | -28,5 | -28,5 | -59,8 | -59,8 | -78,3 | -78,3 | 4,4 | 4,4 | ||
| Pretax margin (%) | -60,2 | N/A | N/A | 12,3 | 12,3 | 2,1 | 2,1 | -14,3 | -14,3 | -29,4 | -29,4 | -60,2 | -60,2 | -78,9 | -78,9 | 3,8 | 3,8 | ||
| Net margin (%) | -47,8 | N/A | N/A | 11,9 | 11,9 | 0,2 | 0,2 | -12,2 | -12,2 | -26,6 | -26,6 | -47,8 | -47,8 | -78,9 | -78,9 | 3,8 | 3,8 | ||
| Growth rates Y/Y | 2013 | 2013 | 2014 | 2014 | 2015 | 2015 | 2016 | 2016 | 2017 | 2017 | 2018 | 2018 | 2019 | 2019 | 2020 | 2020 | |||
| Sales growth (%) | -20 | N/A | N/A | N/A | N/A | -19,5 | -19,5 | -11,5 | -11,5 | -13,6 | -13,6 | -20 | -20 | 5 | 5 | 5 | 5 | ||
| EBITDA growth (%) | -13,8 | N/A | N/A | 0 | 0 | -49 | -49 | -112,9 | -112,9 | -556 | -556 | -13,8 | -13,8 | -208,7 | -208,7 | 132,6 | 132,6 | ||
| EBIT growth (%) | -67,8 | N/A | N/A | 0 | 0 | -79,4 | -79,4 | -455,4 | -455,4 | -85 | -85 | -67,8 | -67,8 | -37,7 | -37,7 | 105,9 | 105,9 | ||
| Net profit growth (%) | -43,7 | N/A | N/A | 0 | 0 | -98,5 | -98,5 | -5029,6 | -5029,6 | -87,6 | -87,6 | -43,7 | -43,7 | -73,5 | -73,5 | 105,1 | 105,1 | ||
| EPS growth (%) | 57,5 | N/A | N/A | 0 | 0 | -98,5 | -98,5 | -17740,3 | -17740,3 | -87,6 | -87,6 | 57,5 | 57,5 | -73,5 | -73,5 | 105,1 | 105,1 | ||
| Profitability | 2013 | 2013 | 2014 | 2014 | 2015 | 2015 | 2016 | 2016 | 2017 | 2017 | 2018 | 2018 | 2019 | 2019 | 2020 | 2020 | |||
| ROE (%) | -12,1 | N/A | N/A | 18,3 | 18,3 | 0,1 | 0,1 | -5,3 | -5,3 | -8,7 | -8,7 | -12,1 | -12,1 | -21,5 | -21,5 | 1 | 1 | ||
| ROE Adj (%) | -12,1 | N/A | N/A | 18,3 | 18,3 | 0,1 | 0,1 | -5,3 | -5,3 | -8,7 | -8,7 | -12,1 | -12,1 | -21,5 | -21,5 | 1 | 1 | ||
| ROCE (%) | -17,4 | N/A | N/A | 21,3 | 21,3 | 1,9 | 1,9 | -5,3 | -5,3 | -9,7 | -9,7 | -17,4 | -17,4 | -26,6 | -26,6 | 1,5 | 1,5 | ||
| ROCE Adj(%) | -17,4 | N/A | N/A | 21,3 | 21,3 | 1,9 | 1,9 | -5,3 | -5,3 | -9,7 | -9,7 | -17,4 | -17,4 | -26,6 | -26,6 | 1,5 | 1,5 | ||
| ROIC (%) | -11,1 | N/A | N/A | 15,6 | 15,6 | 0,2 | 0,2 | -4,7 | -4,7 | -8,8 | -8,8 | -11,1 | -11,1 | -18 | -18 | 1,1 | 1,1 | ||
| ROIC Adj (%) | -11,1 | N/A | N/A | 15,6 | 15,6 | 0,2 | 0,2 | -4,7 | -4,7 | -8,8 | -8,8 | -11,1 | -11,1 | -18 | -18 | 1,1 | 1,1 | ||
| Adj earnings numbers | 2013 | 2013 | 2014 | 2014 | 2015 | 2015 | 2016 | 2016 | 2017 | 2017 | 2018 | 2018 | 2019 | 2019 | 2020 | 2020 | |||
| EBITDA Adj | -8 | 0 | 0 | 17 | 17 | 8 | 8 | -1 | -1 | -7 | -7 | -8 | -8 | -25 | -25 | 8 | 8 | ||
| EBITDA Adj margin (%) | -21,3 | N/A | N/A | 21,3 | 21,3 | 13,5 | 13,5 | -2 | -2 | -15 | -15 | -21,3 | -21,3 | -62,6 | -62,6 | 19,4 | 19,4 | ||
| EBITA Adj | -23 | 0 | 0 | 10 | 10 | 2 | 2 | -7 | -7 | -14 | -14 | -23 | -23 | -32 | -32 | 2 | 2 | ||
| EBITA Adj margin (%) | -59,8 | N/A | N/A | 13 | 13 | 3,3 | 3,3 | -13,3 | -13,3 | -28,5 | -28,5 | -59,8 | -59,8 | -78,3 | -78,3 | 4,4 | 4,4 | ||
| EBIT Adj | -23 | 0 | 0 | 10 | 10 | 2 | 2 | -7 | -7 | -14 | -14 | -23 | -23 | -32 | -32 | 2 | 2 | ||
| EBIT Adj margin (%) | -59,8 | N/A | N/A | 13 | 13 | 3,3 | 3,3 | -13,3 | -13,3 | -28,5 | -28,5 | -59,8 | -59,8 | -78,3 | -78,3 | 4,4 | 4,4 | ||
| Pretax profit Adj | -23 | 0 | 0 | 10 | 10 | 1 | 1 | -8 | -8 | -14 | -14 | -23 | -23 | -32 | -32 | 2 | 2 | ||
| Net profit Adj | -18 | 0 | 0 | 9 | 9 | 0 | 0 | -7 | -7 | -13 | -13 | -18 | -18 | -32 | -32 | 2 | 2 | ||
| Net profit to shareholders Adj | -18 | 0 | 0 | 9 | 9 | 0 | 0 | -7 | -7 | -13 | -13 | -18 | -18 | -32 | -32 | 2 | 2 | ||
| Net Adj margin (%) | -47,8 | N/A | N/A | 11,9 | 11,9 | 0,2 | 0,2 | -12,2 | -12,2 | -26,6 | -26,6 | -47,8 | -47,8 | -78,9 | -78,9 | 3,8 | 3,8 |
| SEKm | 2013 | 2013 | 2014 | 2014 | 2015 | 2015 | 2016 | 2016 | 2017 | 2017 | 2018 | 2018 | 2019e | 2019 | 2020e | 2020 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | -8 | 0 | 0 | 17 | 17 | 8 | 8 | -1 | -1 | -7 | -7 | -8 | -8 | -25 | -25 | 8 | 8 | ||
| Net financial items | 0 | 0 | 0 | -1 | -1 | -1 | -1 | -1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Paid tax | 5 | 0 | 0 | 0 | 0 | -1 | -1 | 1 | 1 | 1 | 1 | 5 | 5 | 0 | 0 | 0 | 0 | ||
| Non-cash items | 0 | 0 | 0 | -3 | -3 | -22 | -22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Cash flow before change in WC | -4 | 0 | 0 | 13 | 13 | -15 | -15 | -1 | -1 | -6 | -6 | -4 | -4 | -25 | -25 | 8 | 8 | ||
| Change in WC | -29 | 0 | 0 | -12 | -12 | -4 | -4 | 2 | 2 | -4 | -4 | -29 | -29 | 21 | 21 | 0 | 0 | ||
| Operating cash flow | -6 | 0 | 0 | 1 | 1 | -19 | -19 | -4 | -4 | -19 | -19 | -6 | -6 | -14 | -14 | -8 | -8 | ||
| CAPEX tangible fixed assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| CAPEX intangible fixed assets | -13 | 0 | 0 | -111 | -111 | -10 | -10 | -10 | -10 | -13 | -13 | -13 | -13 | -11 | -11 | -9 | -9 | ||
| Acquisitions and disposals | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Free cash flow | -19 | 0 | 0 | -110 | -110 | -30 | -30 | -15 | -15 | -32 | -32 | -19 | -19 | -25 | -25 | -18 | -18 | ||
| Dividend paid | 46 | 0 | 0 | 0 | 0 | 23 | 23 | 15 | 15 | 40 | 40 | 46 | 46 | 0 | 0 | 0 | 0 | ||
| Share issues and buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other non cash items | -26 | 0 | 0 | 114 | 114 | 1 | 1 | -6 | -6 | 18 | 18 | -26 | -26 | 43 | 43 | 32 | 32 | ||
| Decrease in net IB debt | 1 | 0 | 0 | 4 | 4 | -5 | -5 | -6 | -6 | 26 | 26 | 1 | 1 | 18 | 18 | 15 | 15 | ||
| Balance Sheet (SEKm) | 2013 | 2013 | 2014 | 2014 | 2015 | 2015 | 2016 | 2016 | 2017 | 2017 | 2018 | 2018 | 2019 | 2019 | 2020 | 2020 | |||
| Goodwill | 29 | 0 | 0 | 53 | 53 | 47 | 47 | 41 | 41 | 35 | 35 | 29 | 29 | 24 | 24 | 18 | 18 | ||
| Indefinite intangible assets | 103 | 0 | 0 | 58 | 58 | 68 | 68 | 79 | 79 | 91 | 91 | 103 | 103 | 120 | 120 | 136 | 136 | ||
| Definite intangible assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Tangible fixed assets | 2 | 0 | 0 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | -4 | -4 | ||
| Other fixed assets | 12 | 0 | 0 | 4 | 4 | 4 | 4 | 3 | 3 | 6 | 6 | 12 | 12 | 12 | 12 | 12 | 12 | ||
| Fixed assets | 146 | 0 | 0 | 118 | 118 | 122 | 122 | 126 | 126 | 135 | 135 | 146 | 146 | 156 | 156 | 160 | 160 | ||
| Inventories | 34 | 0 | 0 | 12 | 12 | 16 | 16 | 20 | 20 | 17 | 17 | 34 | 34 | 26 | 26 | 26 | 26 | ||
| Receivables | 12 | 0 | 0 | 2 | 2 | 3 | 3 | 2 | 2 | 3 | 3 | 12 | 12 | 0 | 0 | 0 | 0 | ||
| Other current assets | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Cash and liquid assets | 9 | 0 | 0 | 20 | 20 | 13 | 13 | 13 | 13 | 21 | 21 | 9 | 9 | 38 | 38 | 68 | 68 | ||
| Total assets | 202 | 0 | 0 | 155 | 155 | 155 | 155 | 164 | 164 | 180 | 180 | 202 | 202 | 220 | 220 | 255 | 255 | ||
| Shareholders equity | 138 | 0 | 0 | 102 | 102 | 127 | 127 | 130 | 130 | 165 | 165 | 138 | 138 | 157 | 157 | 176 | 176 | ||
| Minority | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Total equity | 138 | 0 | 0 | 102 | 102 | 127 | 127 | 130 | 130 | 165 | 165 | 138 | 138 | 157 | 157 | 176 | 176 | ||
| Long-term debt | 1 | 0 | 0 | 15 | 15 | 12 | 12 | 8 | 8 | 1 | 1 | 1 | 1 | 11 | 11 | 27 | 27 | ||
| Pension debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Convertible debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Deferred tax | 0 | 0 | 0 | 3 | 3 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other long-term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Short-term debt | 0 | 0 | 0 | 6 | 6 | 6 | 6 | 16 | 16 | 7 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Accounts payable | 0 | 0 | 0 | 2 | 2 | 3 | 3 | 7 | 7 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other current liabilities | 63 | 0 | 0 | 27 | 27 | 5 | 5 | 2 | 2 | 3 | 3 | 63 | 63 | 51 | 51 | 51 | 51 | ||
| Total liabilities and equity | 164 | 0 | 0 | 0 | 0 | 0 | 0 | 155 | 155 | 155 | 155 | 164 | 164 | 180 | 180 | 202 | 202 | ||
| Net IB debt | -20 | 0 | 0 | -4 | -4 | 1 | 1 | 7 | 7 | -19 | -19 | -20 | -20 | -38 | -38 | -53 | -53 | ||
| Net IB debt excl. pension debt | -20 | 0 | 0 | -4 | -4 | 1 | 1 | 7 | 7 | -19 | -19 | -20 | -20 | -38 | -38 | -53 | -53 | ||
| Capital invested | 181 | 0 | 0 | 126 | 126 | 134 | 134 | 137 | 137 | 146 | 146 | 181 | 181 | 170 | 170 | 175 | 175 | ||
| Working capital | 46 | 0 | 0 | 12 | 12 | 16 | 16 | 14 | 14 | 18 | 18 | 46 | 46 | 26 | 26 | 26 | 26 | ||
| EV breakdown | 2013 | 2013 | 2014 | 2014 | 2015 | 2015 | 2016 | 2016 | 2017 | 2017 | 2018 | 2018 | 2019 | 2019 | 2020 | 2020 | |||
| Market cap. diluted (m) | 307 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 82 | 82 | 307 | 307 | 307 | 307 | 307 | 307 | ||
| Net IB debt Adj | -20 | 0 | 0 | -4 | -4 | 1 | 1 | 7 | 7 | -19 | -19 | -20 | -20 | -38 | -38 | -53 | -53 | ||
| Market value of minority | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Reversal of shares and participations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Reversal of conv. debt assumed equity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| EV | 287 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 63 | 63 | 287 | 287 | 269 | 269 | 255 | 255 | ||
| Capital efficiency (%) | 2013 | 2013 | 2014 | 2014 | 2015 | 2015 | 2016 | 2016 | 2017 | 2017 | 2018 | 2018 | 2019 | 2019 | 2020 | 2020 | |||
| Total assets turnover (%) | 20,1 | N/A | N/A | 100,8 | 100,8 | 40,6 | 40,6 | 34,9 | 34,9 | 28 | 28 | 20,1 | 20,1 | 19,1 | 19,1 | 17,9 | 17,9 | ||
| Capital invested turnover (%) | 23,5 | N/A | N/A | 124,1 | 124,1 | 48,4 | 48,4 | 41,1 | 41,1 | 34 | 34 | 23,5 | 23,5 | 23 | 23 | 24,6 | 24,6 | ||
| Capital employed turnover (%) | 29,1 | N/A | N/A | 158,9 | 158,9 | 55,5 | 55,5 | 41,9 | 41,9 | 33,9 | 33,9 | 29,1 | 29,1 | 34 | 34 | 34,9 | 34,9 | ||
| Inventories / sales (%) | 66,9 | N/A | N/A | 7,8 | 7,8 | 22,8 | 22,8 | 32,5 | 32,5 | 38,6 | 38,6 | 66,9 | 66,9 | 74,1 | 74,1 | 60,6 | 60,6 | ||
| Customer advances / sales (%) | 0,2 | N/A | N/A | 0 | 0 | 0,1 | 0,1 | 0,3 | 0,3 | 0,3 | 0,3 | 0,2 | 0,2 | 0 | 0 | 0 | 0 | ||
| Payables / sales (%) | 3,5 | N/A | N/A | 1,4 | 1,4 | 3,7 | 3,7 | 8,5 | 8,5 | 10,1 | 10,1 | 3,5 | 3,5 | 0 | 0 | 0 | 0 | ||
| Working capital / sales (%) | 83,2 | N/A | N/A | 7,9 | 7,9 | 22,8 | 22,8 | 27,4 | 27,4 | 33 | 33 | 83,2 | 83,2 | 89,2 | 89,2 | 60,6 | 60,6 | ||
| Financial risk and debt service | 2013 | 2013 | 2014 | 2014 | 2015 | 2015 | 2016 | 2016 | 2017 | 2017 | 2018 | 2018 | 2019 | 2019 | 2020 | 2020 | |||
| Net debt / equity (%) | -14,6 | N/A | N/A | -3,8 | -3,8 | 1,2 | 1,2 | 5,5 | 5,5 | -11,5 | -11,5 | -14,6 | -14,6 | -24,3 | -24,3 | -29,9 | -29,9 | ||
| Net debt / market cap (%) | -8,8 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -22,4 | -22,4 | -8,8 | -8,8 | -12,4 | -12,4 | -17,2 | -17,2 | ||
| Equity ratio (%) | 68,6 | N/A | N/A | 66 | 66 | 81,6 | 81,6 | 79,5 | 79,5 | 91,8 | 91,8 | 68,6 | 68,6 | 71,7 | 71,7 | 69,3 | 69,3 | ||
| Net IB debt adj. / equity (%) | -14,6 | N/A | N/A | -3,8 | -3,8 | 1,2 | 1,2 | 5,5 | 5,5 | -11,5 | -11,5 | -14,6 | -14,6 | -24,3 | -24,3 | -29,9 | -29,9 | ||
| Current ratio (%) | 88,9 | N/A | N/A | 105,6 | 105,6 | 235,9 | 235,9 | 151,8 | 151,8 | 341 | 341 | 88,9 | 88,9 | 125,9 | 125,9 | 184,9 | 184,9 | ||
| EBITDA / net interest (%) | -4501,4 | N/A | N/A | 3230,8 | 3230,8 | 1084,8 | 1084,8 | -201,1 | -201,1 | -1625,7 | -1625,7 | -4501,4 | -4501,4 | -10916 | -10916 | 3555,5 | 3555,5 | ||
| Net IB debt / EBITDA (%) | 247,8 | N/A | N/A | -23,4 | -23,4 | 17,6 | 17,6 | -654,2 | -654,2 | 265,1 | 265,1 | 247,8 | 247,8 | 151,3 | 151,3 | -641,6 | -641,6 | ||
| Interest cover (%) | -12640,2 | N/A | N/A | 1190,5 | 1190,5 | 256,3 | 256,3 | -829,8 | -829,8 | -3050,8 | -3050,8 | -12640,2 | -12640,2 | -13669,3 | -13669,3 | 802,1 | 802,1 |
| SEKm | 2013 | 2013 | 2014 | 2014 | 2015 | 2015 | 2016 | 2016 | 2017 | 2017 | 2018 | 2018 | 2019e | 2019 | 2020e | 2020 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares outstanding adj. | 38 | 0 | 0 | 39 | 39 | 40 | 40 | 11 | 11 | 11 | 11 | 38 | 38 | 38 | 38 | 38 | 38 | ||
| Fully diluted shares Adj | 38 | 0 | 0 | 39 | 39 | 40 | 40 | 11 | 11 | 11 | 11 | 38 | 38 | 38 | 38 | 38 | 38 | ||
| EPS | -0,49 | 0 | 0 | 0,24 | 0,24 | 0 | 0 | -0,61 | -0,61 | -1,15 | -1,15 | -0,49 | -0,49 | -0,84 | -0,84 | 0,04 | 0,04 | ||
| Dividend per share Adj | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| EPS Adj | -0,49 | 0 | 0 | 0,24 | 0,24 | 0 | 0 | -0,61 | -0,61 | -1,15 | -1,15 | -0,49 | -0,49 | -0,84 | -0,84 | 0,04 | 0,04 | ||
| BVPS | 3,67 | 0 | 0 | 2,6 | 2,6 | 3,17 | 3,17 | 11,68 | 11,68 | 14,8 | 14,8 | 3,67 | 3,67 | 4,18 | 4,18 | 4,68 | 4,68 | ||
| BVPS Adj | 2,89 | 0 | 0 | 1,25 | 1,25 | 1,99 | 1,99 | 7,98 | 7,98 | 11,63 | 11,63 | 2,89 | 2,89 | 3,55 | 3,55 | 4,21 | 4,21 | ||
| Net IB debt / share | -0,5 | N/A | N/A | -0,1 | -0,1 | 0 | 0 | 0,6 | 0,6 | -1,7 | -1,7 | -0,5 | -0,5 | -1 | -1 | -1,4 | -1,4 | ||
| Share price | 6,1 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 7,62 | 7,62 | 6,1 | 6,1 | 8,16 | 8,16 | 8,16 | 8,16 | ||
| Market cap. (m) | 230 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 85 | 85 | 230 | 230 | 307 | 307 | 307 | 307 | ||
| Valuation | 2013 | 2013 | 2014 | 2014 | 2015 | 2015 | 2016 | 2016 | 2017 | 2017 | 2018 | 2018 | 2019 | 2019 | 2020 | 2020 | |||
| P/E | -16,8 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -6,4 | -6,4 | -16,8 | -16,8 | -9,7 | -9,7 | 189,4 | 189,4 | ||
| EV/sales | 7,48 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1,3 | 1,3 | 7,48 | 7,48 | 6,67 | 6,67 | 6,01 | 6,01 | ||
| EV/EBITDA | -35,1 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -8,7 | -8,7 | -35,1 | -35,1 | -10,7 | -10,7 | 31 | 31 | ||
| EV/EBITA | -12,5 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -4,6 | -4,6 | -12,5 | -12,5 | -8,5 | -8,5 | 137,3 | 137,3 | ||
| EV/EBIT | -12,5 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -4,6 | -4,6 | -12,5 | -12,5 | -8,5 | -8,5 | 137,3 | 137,3 | ||
| Dividend yield (%) | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| FCF yield (%) | -6,2 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -38,8 | -38,8 | -6,2 | -6,2 | -8,1 | -8,1 | -5,8 | -5,8 | ||
| P/BVPS | 2,22 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0,5 | 0,5 | 2,22 | 2,22 | 1,95 | 1,95 | 1,74 | 1,74 | ||
| P/BVPS Adj | 2,82 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0,63 | 0,63 | 2,82 | 2,82 | 2,3 | 2,3 | 1,94 | 1,94 | ||
| P/E Adj | -16,8 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -6,4 | -6,4 | -16,8 | -16,8 | -9,7 | -9,7 | 189,4 | 189,4 | ||
| EV/EBITDA Adj | -35,1 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -8,7 | -8,7 | -35,1 | -35,1 | -10,7 | -10,7 | 31 | 31 | ||
| EV/EBITA Adj | -12,5 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -4,6 | -4,6 | -12,5 | -12,5 | -8,5 | -8,5 | 137,3 | 137,3 | ||
| EV/EBIT Adj | -12,5 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -4,6 | -4,6 | -12,5 | -12,5 | -8,5 | -8,5 | 137,3 | 137,3 | ||
| EV/cap. employed | 2,4 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0,4 | 0,4 | 2,4 | 2,4 | 2,3 | 2,3 | 2,1 | 2,1 | ||
| Investment ratios | 2013 | 2013 | 2014 | 2014 | 2015 | 2015 | 2016 | 2016 | 2017 | 2017 | 2018 | 2018 | 2019 | 2019 | 2020 | 2020 | |||
| Capex / sales | 33,9 | N/A | N/A | 142 | 142 | 16,7 | 16,7 | 18,3 | 18,3 | 26,1 | 26,1 | 33,9 | 33,9 | 26,3 | 26,3 | 22,3 | 22,3 | ||
| Capex / depreciation | 88,1 | N/A | N/A | 1694,6 | 1694,6 | 163,3 | 163,3 | 161,2 | 161,2 | 192,6 | 192,6 | 88,1 | 88,1 | 166,9 | 166,9 | 148,5 | 148,5 | ||
| Capex tangibles / tangible fixed assets | 0 | N/A | N/A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Capex intangibles / definite intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| Depreciation on intangibles / definite intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| Depreciation on tangibles / tangibles | 552,3 | N/A | N/A | 23,9 | 23,9 | 20,4 | 20,4 | 16,5 | 16,5 | 30,8 | 30,8 | 552,3 | 552,3 | 41,4 | 41,4 | -10,9 | -10,9 |
Equity research
INTERVACC
Intervacc - Dose optimized: key to Strangvac positioning
6 December 2018 Intervacc Post-results comment
Company news
INTERVACC
Ny VD i innovativa och växande vaccinbolaget Intervacc
12 December 2018
Delårsrapport Intervacc AB januari - september 2018
29 November 2018
Main shareholders
Intervacc
| Main shareholders | Share capital % | Voting shares % | Verified | |
|---|---|---|---|---|
| Thomas Eklund | 8.9 % | 8.9 % | 31 Dec 2018 | |
| Avanza Pension | 7.8 % | 7.8 % | 31 Dec 2018 | |
| Newton Aguiar | 7.6 % | 7.6 % | 18 May 2018 | |
| Knutsson Holding AB | 5.6 % | 5.6 % | 31 Dec 2018 | |
| Nexttobe AB | 5.3 % | 5.3 % | 31 Dec 2018 | |
| K Janzon Holding AB | 4.3 % | 4.3 % | 31 Dec 2018 | |
| N.R Bergman Holding AB | 4.2 % | 4.2 % | 31 Dec 2018 | |
| Fredrik Lundgren | 4.1 % | 4.1 % | 31 Dec 2018 | |
| Björn Sjöstrand | 3.3 % | 3.3 % | 31 Dec 2018 | |
| Nordnet Pensionsförsäkring | 3.1 % | 3.1 % | 31 Dec 2018 | |
| Source: Holdings by Modular Finance AB | ||||
Insider list
Intervacc
| Name | Code | Quantity | Date | |
|---|---|---|---|---|
| Bacilltech Aktiebolag | + 14 723 | BUY | + 14 723 | 11 Jan 2019 |
| Bacilltech Aktiebolag | + 57 660 | BUY | + 57 660 | 10 Jan 2019 |
| Kenneth Jansson | -1 552 000 | GIFT | -1 552 000 | 27 Mar 2018 |
| Kenneth Jansson | - 41 250 | GIFT | - 41 250 | 26 Mar 2018 |
| Kenneth Jansson | - 41 250 | GIFT | - 41 250 | 26 Mar 2018 |
QUICK FACTS
- Andreas Andersson
- Rune Bergman
- Healthcare
- www.intervacc.com
- First North
- 311,9 MSEK
- IVACC
- Q4 Report 22 Feb 2019
QUICK FACTS
- CEO
- Andreas Andersson
- Chairman
- Rune Bergman
- List
- First North
- Sector
- Healthcare
QUICK FACTS
- Market Cap
- 311,9 MSEK
- Ticker
- IVACC
- Next Event
- 22 Feb 2019
- Website
- www.intervacc.com
Latest articles
-
Ny VD i innovativa och växande vaccinbolaget Intervacc
12 Dec 2018 / Press release
-
Intervacc - Interview with CEO Jan-Ingmar Flock (in Swedish)
6 Dec 2018 / Media
-
Intervacc - Dose optimized: key to Strangvac positioning
6 Dec 2018 / Analys
-
Intervacc - Company presentation with CEO Jan-Ingmar Flock (in Swedish)
5 Dec 2018 / Media
-
Livesändning - Introduce Investor Day (4 Dec 2018)
4 Dec 2018 / Article
